
Cappella, Inc
Novel stent platform for bifurcated Coronary Artery Disease
| Company | Cappella, Inc |
|---|---|
| URL | http://www.cappella-med.com/ |
Positive Long Term Clinical Data of the Cappella Sideguard® Stent System Announced at TCT 2011
Cappella Medical Devices Ltd announced at the 2011 TCT (Transcatheter Cardiovascular Therapeutics) Conference in San Francisco results from several long term studies of its Sideguard® technology.
Cappella Medical Announces Excellent Long Term Follow-Up Clinical Data on Its Sideguard® Technology
Cappella Medical Devices Ltd announced initial long term follow up data for its innovative Sideguard® coronary sidebranch stent from Manchester Royal Infirmary in Manchester, United Kingdom. Long term follow up data on the Sideguard stent was obtained from 38 patients that received the stent as early as March 2010
MVC Corporation Changes Name to Mitsui & Co. Global Investment, Ltd.
MCVP Changes Name and Relocates Office
Notice on Relocation of MVC Head Office
Mitsui Ventures invested USD 5 M in S*BIO
Boehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.

